A Study of miRNA 371 in Patients With Germ Cell Tumors

Inclusion Criteria: * Patients must have a new diagnosis of a germ cell tumor. confirmed pathologically or serologically (diagnostic elevation of human chorionic gonadotropin \[HCG\]/alpha-fetoprotein \[AFP\]). All primary sites, stages, histological subtypes of germ cell tumor are eligible. Metachronous second primary germ cell tumors are eligible * If surgery is planned, male patients with clinical stage I testicular cancer must have orchiectomy completed within 42 days prior to registration * Patients must be registered within 42 days after diagnosis and prior to initiation of a management plan or treatment for the disease * Patients must have initial imaging, laboratory and other clinical evaluations (see below) performed within 42 days prior to registration. Imaging reports, pathology reports and performance status will be collected * Patients must have beta-human chorionic gonadotropin (beta- HCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) assessments within 42 days prior to registration * NOTE: If the patient had an orchiectomy prior to registration, report tumor marker values before and after surgery on the Baseline Tumor Marker form * Patients must have risk of relapse assessment determined by the local investigator prior to registration * Patients must agree to submit required specimens for defined translational medicine studies. These specimens are drawn at the same time as standard laboratory evaluations (beta-HCG, AFP, and LDH); NOTE: Ideally, …